Ranjan Dohil1, Betty L Cabrera. 1. Department of Pediatrics, Rady Children's Hospital-San Diego, University of California San Diego, 3030 Children's Way, San Diego, CA 92123, USA. rdohil@ucsd.edu
Abstract
BACKGROUND: Patients with nephropathic cystinosis are required to take 6-hourly immediate-release cysteamine (Cystagon®) to reduce disease progression. This arduous regimen affects quality of life, disrupts sleep, and may result in non-compliance with therapy. Enteric-coated cysteamine bitartrate (EC-cysteamine) was developed as a "proof-of-concept" formulation for twice-daily ingestion. Previous reports have shown this therapy to be effective up to a mean of 14 months. CASE-DIAGNOSIS/TREATMENT: Two subjects (aged 13 and 15 years) received EC-cysteamine for 5-6 years at 60-65 % of their previous total daily dose of immediate-release cysteamine given at 6-h intervals. White blood cell (WBC) cystine levels were monitored every 1-3 months. CONCLUSION: The administration of EC-cysteamine did not result in any change in mean trough WBC cystine levels or any deterioration in the estimated glomerular filtration rate, thyroid, or liver function, suggesting that delayed-release, twice-daily EC-cysteamine is an effective long-term treatment alternative to immediate-release cysteamine given at 6-h intervals.
BACKGROUND:Patients with nephropathic cystinosis are required to take 6-hourly immediate-release cysteamine (Cystagon®) to reduce disease progression. This arduous regimen affects quality of life, disrupts sleep, and may result in non-compliance with therapy. Enteric-coated cysteamine bitartrate (EC-cysteamine) was developed as a "proof-of-concept" formulation for twice-daily ingestion. Previous reports have shown this therapy to be effective up to a mean of 14 months. CASE-DIAGNOSIS/TREATMENT: Two subjects (aged 13 and 15 years) received EC-cysteamine for 5-6 years at 60-65 % of their previous total daily dose of immediate-release cysteamine given at 6-h intervals. White blood cell (WBC) cystine levels were monitored every 1-3 months. CONCLUSION: The administration of EC-cysteamine did not result in any change in mean trough WBC cystine levels or any deterioration in the estimated glomerular filtration rate, thyroid, or liver function, suggesting that delayed-release, twice-daily EC-cysteamine is an effective long-term treatment alternative to immediate-release cysteamine given at 6-h intervals.
Authors: Elena N Levtchenko; Carin M van Dael; Addy C de Graaf-Hess; Martijn J G Wilmer; Lambertus P van den Heuvel; Leo A Monnens; Henk J Blom Journal: Pediatr Nephrol Date: 2005-10-27 Impact factor: 3.714
Authors: Craig B Langman; Larry A Greenbaum; Minnie Sarwal; Paul Grimm; Patrick Niaudet; Georges Deschênes; Elisabeth Cornelissen; Denis Morin; Pierre Cochat; Debora Matossian; Segolene Gaillard; Mary Jo Bagger; Patrice Rioux Journal: Clin J Am Soc Nephrol Date: 2012-05-03 Impact factor: 8.237
Authors: Ranjan Dohil; Meredith Fidler; Bruce A Barshop; Jon Gangoiti; Reena Deutsch; Michael Martin; Jerry A Schneider Journal: J Pediatr Date: 2006-06 Impact factor: 4.406
Authors: Barbara C Sonies; Phaedra Almajid; Robert Kleta; Isa Bernardini; William A Gahl Journal: Medicine (Baltimore) Date: 2005-05 Impact factor: 1.889
Authors: V Shotelersuk; D Larson; Y Anikster; G McDowell; R Lemons; I Bernardini; J Guo; J Thoene; W A Gahl Journal: Am J Hum Genet Date: 1998-11 Impact factor: 11.025
Authors: Danielle Armas; Robert J Holt; Nils F Confer; Gregg C Checani; Mohammad Obaidi; Yuli Xie; Meg Brannagan Journal: Adv Ther Date: 2018-02-06 Impact factor: 3.845